vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and Vir Biotechnology, Inc. (VIR). Click either name above to swap in a different company.
Vir Biotechnology, Inc. is the larger business by last-quarter revenue ($240.0K vs $169.0K, roughly 1.4× Aligos Therapeutics, Inc.). On growth, Aligos Therapeutics, Inc. posted the faster year-over-year revenue change (-72.1% vs -89.9%). Over the past eight quarters, Aligos Therapeutics, Inc.'s revenue compounded faster (-50.7% CAGR vs -88.0%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing innovative therapies and vaccines to address serious infectious diseases including COVID-19, hepatitis B, HIV, and influenza. It operates primarily in the global biopharmaceutical market, collaborating with leading industry partners to advance its pipeline of targeted immune-based solutions for patient populations worldwide.
ALGS vs VIR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $240.0K |
| Net Profit | — | $-163.1M |
| Gross Margin | — | — |
| Operating Margin | — | -72267.9% |
| Net Margin | — | -67975.4% |
| Revenue YoY | -72.1% | -89.9% |
| Net Profit YoY | 75.8% | 23.7% |
| EPS (diluted) | — | $-1.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | — | ||
| Q3 25 | $741.0K | $240.0K | ||
| Q2 25 | $965.0K | $1.2M | ||
| Q1 25 | $311.0K | $3.0M | ||
| Q4 24 | $606.0K | $12.4M | ||
| Q3 24 | $1.3M | $2.4M | ||
| Q2 24 | $1.1M | $3.1M | ||
| Q1 24 | $694.0K | $56.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.5M | $-163.1M | ||
| Q2 25 | $-15.9M | $-111.0M | ||
| Q1 25 | $43.1M | $-121.0M | ||
| Q4 24 | $-82.2M | — | ||
| Q3 24 | $-19.3M | $-213.7M | ||
| Q2 24 | $5.1M | $-138.4M | ||
| Q1 24 | $-34.9M | $-65.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 99.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 97.9% | ||
| Q2 24 | — | 98.3% | ||
| Q1 24 | — | 99.9% |
| Q4 25 | — | — | ||
| Q3 25 | -3827.4% | -72267.9% | ||
| Q2 25 | -1924.0% | -9754.3% | ||
| Q1 25 | -6187.5% | -4602.5% | ||
| Q4 24 | -3393.2% | — | ||
| Q3 24 | -1610.5% | -9718.7% | ||
| Q2 24 | -2489.5% | -5158.7% | ||
| Q1 24 | -3176.7% | -142.0% |
| Q4 25 | — | — | ||
| Q3 25 | -4256.0% | -67975.4% | ||
| Q2 25 | -1643.8% | -9139.9% | ||
| Q1 25 | 13854.7% | -3989.6% | ||
| Q4 24 | -13556.1% | — | ||
| Q3 24 | -1540.7% | -8979.7% | ||
| Q2 24 | 477.0% | -4500.1% | ||
| Q1 24 | -5023.5% | -115.8% |
| Q4 25 | — | — | ||
| Q3 25 | $-3.04 | $-1.17 | ||
| Q2 25 | $-1.53 | $-0.80 | ||
| Q1 25 | $-2.11 | $-0.88 | ||
| Q4 24 | $-13.10 | — | ||
| Q3 24 | $-3.07 | $-1.56 | ||
| Q2 24 | $0.81 | $-1.02 | ||
| Q1 24 | $-5.58 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $497.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $796.1M |
| Total Assets | $88.5M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | — | ||
| Q3 25 | $99.1M | $497.8M | ||
| Q2 25 | $122.9M | $598.7M | ||
| Q1 25 | $137.9M | $790.9M | ||
| Q4 24 | $56.9M | $901.0M | ||
| Q3 24 | $74.9M | $909.0M | ||
| Q2 24 | $94.5M | $1.1B | ||
| Q1 24 | $112.7M | $1.1B |
| Q4 25 | $53.5M | — | ||
| Q3 25 | $71.8M | $796.1M | ||
| Q2 25 | $101.9M | $947.5M | ||
| Q1 25 | $116.4M | $1.0B | ||
| Q4 24 | $-29.0M | $1.2B | ||
| Q3 24 | $50.1M | $1.2B | ||
| Q2 24 | $67.2M | $1.4B | ||
| Q1 24 | $59.8M | $1.5B |
| Q4 25 | $88.5M | — | ||
| Q3 25 | $109.8M | $1.0B | ||
| Q2 25 | $134.7M | $1.2B | ||
| Q1 25 | $150.7M | $1.3B | ||
| Q4 24 | $70.1M | $1.4B | ||
| Q3 24 | $88.4M | $1.5B | ||
| Q2 24 | $108.8M | $1.7B | ||
| Q1 24 | $127.9M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-167.6M |
| Free Cash FlowOCF − Capex | — | $-167.9M |
| FCF MarginFCF / Revenue | — | -69952.9% |
| Capex IntensityCapex / Revenue | — | 132.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-824.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | — | ||
| Q3 25 | $-24.3M | $-167.6M | ||
| Q2 25 | $-15.5M | $-120.2M | ||
| Q1 25 | $-20.9M | $-78.1M | ||
| Q4 24 | $-18.4M | $-446.4M | ||
| Q3 24 | $-20.1M | $-171.5M | ||
| Q2 24 | $-19.5M | $-77.8M | ||
| Q1 24 | $-22.7M | $-109.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-167.9M | ||
| Q2 25 | — | $-122.8M | ||
| Q1 25 | — | $-79.7M | ||
| Q4 24 | — | $-453.7M | ||
| Q3 24 | — | $-174.2M | ||
| Q2 24 | — | $-78.5M | ||
| Q1 24 | — | $-111.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | -69952.9% | ||
| Q2 25 | — | -10111.8% | ||
| Q1 25 | — | -2630.1% | ||
| Q4 24 | — | -3666.2% | ||
| Q3 24 | — | -7321.3% | ||
| Q2 24 | — | -2553.3% | ||
| Q1 24 | — | -197.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | 132.1% | ||
| Q2 25 | — | 209.1% | ||
| Q1 25 | — | 53.7% | ||
| Q4 24 | — | 59.0% | ||
| Q3 24 | — | 116.3% | ||
| Q2 24 | — | 21.7% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
